Finance

Beta
Lists
ALCOX:EPA
NicOx SA
€0.37
-0.40%
(-0.0015) 1D
Jun 5, 5:35:24 PM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for ALCOX...
Open
€0.38
High
€0.38
Low
€0.37
Mkt. cap
34.45M
Avg. vol.
230.68K
Volume
146.40K
52-wk high
€0.65
52-wk low
€0.22
EPS
-€0.03
Shares outstanding
93.46M
No. of employees
10
Open
€0.38
High
€0.38
Low
€0.37
Mkt. cap
34.45M
Avg. vol.
230.68K
Volume
146.40K
52-wk high
€0.65
52-wk low
€0.22
EPS
-€0.03
Shares outstanding
93.46M
No. of employees
10
Analyst outlook
Analyst Ratings
Based on 1 analyst giving stock ratings to ALCOX in the past 3 months
Buy
Buy
1
Hold
0
Sell
0
12 month forecast
Based on 1 Wall Street analyst offering 12 month price targets for ALCOX in the last 3 months.
Highest
Current €0.37
€1.00 (+167.38%)
Average
€1.00 (+167.38%)
Lowest
€1.00 (+167.38%)
News stories
From sources across the web
Profile
Nicox S.A. is a French ophthalmology company developing treatments to maintain vision and improve ocular health. Nicox is headquartered in Sophia Antipolis, France, and its Chairman and CEO is Michele Garufi. Nicox is listed on Euronext Paris and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes. Its pipeline includes three programs in development, and it has two U.S. Food and Drug Administration approved products. Wikipedia
About NicOx SA
CEO-
Employees10
Founded1996
HeadquartersValbonne, Provence-Alpes-Côte d'Azur, France
SectorBiotechnology
Websitenicox.com
Previous reportsAll values in EUR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in EUR
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Revenue
763.05K
763.05K
7.62M
7.62M
Cost of goods sold
2.90M
2.90M
2.22M
2.22M
Cost of revenue
2.90M
2.90M
2.22M
2.22M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
421.39K
421.39K
478.60K
478.60K
Operating expense
441.99K
441.99K
-486.77K
-486.77K
Total operating expenses
3.34M
3.34M
1.73M
1.73M
Operating income
-2.58M
-2.58M
5.89M
5.89M
Other non operating income
-1.50M
-1.50M
-8.56M
-8.56M
EBT including unusual items
-4.47M
-4.47M
3.27M
3.27M
EBT excluding unusual items
-4.47M
-4.47M
-3.81M
-3.81M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
18.06K
18.06K
-967.68K
-967.68K
Net income
-4.47M
-4.47M
3.27M
3.27M
Net profit margin
-586.37%
-586.37%
42.87%
42.87%
Earnings per share
-
-
-
-
Interest and investment income
186.72K
186.72K
66.40K
66.40K
Interest expense
-273.18K
-273.18K
-1.20M
-1.20M
Net interest expenses
-86.46K
-86.46K
-1.14M
-1.14M
Depreciation and amortization charges
2.54K
2.54K
2.31K
2.31K
EBITDA
-2.57M
-2.57M
5.89M
5.89M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer